Reviewing Marker Therapeutics (NASDAQ:MRKR) and PTC Therapeutics (NASDAQ:PTCT)

Marker Therapeutics (NASDAQ:MRKR) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.

Profitability

This table compares Marker Therapeutics and PTC Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	N/A	-56.96%	-47.82%
PTC Therapeutics	-9.17%	N/A	-0.10%

Volatility & Risk

Marker Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Marker Therapeutics and PTC Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1	0	2	1	2.75
PTC Therapeutics	1	3	10	1	2.73

Marker Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 952.52%. PTC Therapeutics has a consensus price target of $99.23, indicating a potential upside of 52.87%. Given Marker Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than PTC Therapeutics.

Valuation & Earnings

This table compares Marker Therapeutics and PTC Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55 million	4.46	-$12.16 million	($0.41)	-2.32
PTC Therapeutics	$1.73 billion	3.13	$682.64 million	($1.40)	-46.36

PTC Therapeutics has higher revenue and earnings than Marker Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

22.4% of Marker Therapeutics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by insiders. Comparatively, 5.3% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Marker Therapeutics beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.

About Marker Therapeutics

Marker Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors. The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia.

About PTC Therapeutics

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.